Ultragenyx Pharmaceutical Statistics
Share Statistics
Ultragenyx Pharmaceutical has 92.34M shares outstanding. The number of shares has increased by 12.16% in one year.
| Shares Outstanding | 92.34M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.19% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 83.35M |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 3.71M, so 4.02% of the outstanding shares have been sold short.
| Short Interest | 3.71M |
| Short % of Shares Out | 4.02% |
| Short % of Float | 4.46% |
| Short Ratio (days to cover) | 5.7 |
Valuation Ratios
The PE ratio is -5.8 and the forward PE ratio is -9.36.
| PE Ratio | -5.8 |
| Forward PE | -9.36 |
| PS Ratio | 8.1 |
| Forward PS | 4.5 |
| PB Ratio | 12.77 |
| P/FCF Ratio | -6.74 |
| PEG Ratio | n/a |
Enterprise Valuation
Ultragenyx Pharmaceutical Inc. has an Enterprise Value (EV) of 3.35B.
| EV / Earnings | -5.52 |
| EV / Sales | 7.71 |
| EV / EBITDA | -6.48 |
| EV / EBIT | -5.88 |
| EV / FCF | -6.42 |
Financial Position
The company has a current ratio of 2.61, with a Debt / Equity ratio of 0.
| Current Ratio | 2.61 |
| Quick Ratio | 2.49 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -8.62 |
Financial Efficiency
Return on equity (ROE) is -2.2% and return on capital (ROIC) is -178.13%.
| Return on Equity (ROE) | -2.2% |
| Return on Assets (ROA) | -0.41% |
| Return on Capital (ROIC) | -178.13% |
| Revenue Per Employee | 340.32K |
| Profits Per Employee | -475.42K |
| Employee Count | 1.28K |
| Asset Turnover | 0.29 |
| Inventory Turnover | 1.33 |
Taxes
| Income Tax | -1.82M |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -12.82% in the last 52 weeks. The beta is 0.58, so Ultragenyx Pharmaceutical 's price volatility has been higher than the market average.
| Beta | 0.58 |
| 52-Week Price Change | -12.82% |
| 50-Day Moving Average | 47.54 |
| 200-Day Moving Average | 47.66 |
| Relative Strength Index (RSI) | 29.19 |
| Average Volume (20 Days) | 768.15K |
Income Statement
In the last 12 months, Ultragenyx Pharmaceutical had revenue of 434.25M and earned -606.64M in profits. Earnings per share was -8.25.
| Revenue | 434.25M |
| Gross Profit | 389.04M |
| Operating Income | -569.21M |
| Net Income | -606.64M |
| EBITDA | -516.45M |
| EBIT | -569.21M |
| Earnings Per Share (EPS) | -8.25 |
Balance Sheet
The company has 213.58M in cash and 43.17M in debt, giving a net cash position of 170.41M.
| Cash & Cash Equivalents | 213.58M |
| Total Debt | 43.17M |
| Net Cash | 170.41M |
| Retained Earnings | -3.39B |
| Total Assets | 1.54B |
| Working Capital | 514.60M |
Cash Flow
In the last 12 months, operating cash flow was -474.81M and capital expenditures -46.77M, giving a free cash flow of -521.57M.
| Operating Cash Flow | -474.81M |
| Capital Expenditures | -46.77M |
| Free Cash Flow | -521.57M |
| FCF Per Share | -7.09 |
Margins
Gross margin is 8.96K%, with operating and profit margins of -13.11K% and -13.97K%.
| Gross Margin | 8.96K% |
| Operating Margin | -13.11K% |
| Pretax Margin | -14.01K% |
| Profit Margin | -13.97K% |
| EBITDA Margin | -118.93% |
| EBIT Margin | -131.08% |
| FCF Margin | -120.11% |
Dividends & Yields
RARE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -19.88% |
| FCF Yield | -13.61% |
Analyst Forecast
The average price target for RARE is $81, which is 95.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $81 |
| Price Target Difference | 95.2% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Scores
| Altman Z-Score | -1.76 |
| Piotroski F-Score | 3 |